CABALETTA BIO, INC. (CABA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$52.02M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$44.30M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$46.59M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$45.91M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$52.02M | (m) | (m) | (m) | $0.00* | -$41.51M* | (m) | $44.43M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$44.30M | (m) | (m) | (m) | $0.00 | -$42.56M | (m) | $37.35M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$46.59M | (m) | (m) | (m) | $78.00K* | -$34.51M* | (m) | $39.82M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$45.91M | (m) | (m) | (m) | $161.00K* | -$30.43M* | (m) | $37.64M | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$37.14M | (m) | (m) | (m) | $785.00K | -$30.80M | (m) | $29.02M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$33.05M | (m) | (m) | (m) | $253.00K* | -$20.32M* | (m) | $26.29M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$30.28M | (m) | (m) | (m) | $770.00K* | -$20.79M* | (m) | $23.43M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$28.03M | (m) | (m) | (m) | $812.00K | -$23.99M | (m) | $21.95M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$18.67M | (m) | (m) | (m) | $65.00K* | -$12.60M* | (m) | $13.79M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$15.89M | (m) | (m) | (m) | $57.00K* | -$11.89M* | (m) | $11.80M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$16.96M | (m) | (m) | (m) | $380.00K | -$12.61M | (m) | $12.44M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$11.78M | (m) | (m) | (m) | $1.09M* | -$9.91M* | (m) | $8.22M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$13.06M | (m) | (m) | (m) | $898.00K* | -$11.53M* | (m) | $9.51M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$13.00M | (m) | (m) | (m) | $147.00K | -$12.81M | (m) | $9.17M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$11.56M | (m) | (m) | (m) | $530.00K* | -$8.34M* | (m) | $8.17M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$11.14M | (m) | (m) | (m) | $388.00K* | -$6.58M* | (m) | $7.85M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$9.71M | (m) | (m) | (m) | $97.00K | -$8.67M | (m) | $6.56M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$8.42M | (m) | (m) | (m) | $162.00K* | -$5.02M* | (m) | $5.65M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$8.19M | (m) | (m) | (m) | $20.00K* | -$7.64M* | (m) | $5.33M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$7.89M | (m) | (m) | (m) | $226.00K | -$4.93M | (m) | $4.62M | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$5.03M | (m) | (m) | (m) | $40.00K* | -$2.08M* | (m) | $3.22M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$3.80M | (m) | (m) | (m) | $200.00K* | -$3.82M* | (m) | $2.66M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$3.99M | (m) | (m) | (m) | $180.00K | -$2.27M | (m) | $2.76M | (m) | $0.00 |
| 2018-09-30 | Reported | (m) | -$3.08M | (m) | (m) | (m) | (m) | (m) | (m) | $2.59M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$172.24M | (m) | (m) | (m) | $1.23M | -$131.08M | (m) | $142.67M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$125.14M | (m) | (m) | (m) | $2.21M | -$88.22M | (m) | $97.20M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$74.66M | (m) | (m) | (m) | $687.00K | -$53.55M | (m) | $55.42M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$54.14M | (m) | (m) | (m) | $2.45M | -$46.38M | (m) | $39.30M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$46.31M | (m) | (m) | (m) | $1.17M | -$34.11M | (m) | $32.49M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$33.83M | (m) | (m) | (m) | $635.00K | -$26.77M | (m) | $21.38M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$18.68M | (m) | (m) | (m) | $693.00K | -$16.05M | (m) | $11.67M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$6.19M | (m) | (m) | (m) | (m) | -$4.66M | (m) | $4.47M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |